VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP
Status:
Completed
Trial end date:
2018-08-30
Target enrollment:
Participant gender:
Summary
The Retinopathy of Prematurity (ROP) is one of the leading causes of blindness on the
pediatric age worldwide. This pathology is characterized for arrest of the normal vascular
and neuronal retina that because of pathological compensatory mechanisms results in
proliferation of vascular tissue that grow in the limit between the vascular retina and the
avascular retina.
The ET-ROP group classified the ROP by those who need treatment immediately or those who
doesn't need treatment, The classification is the following Type 1 ROP-->ROP zone I any stage
with plus, zone I stage 3 without plus, zone II stage 2 y 3 with plus Type 2 ROP --> Zone 1,
Stage 2 or 3 without plus, and Zone II, stage 3 without plus.
The treatment is begun on patient with type 1 ROP and type 2 ROP is maintained in
observation.
Phase:
Phase 4
Details
Lead Sponsor:
Universidad Autonoma de San Luis Potosí
Collaborators:
Francisco Jesus Escalante Padron Hospital Central "Dr. Ignacio Morones Prieto" Leticia Yañez Estrada Marco Martinez Martinez Martha Giselda Rangel Charqueño Mauricio Pierdant Pérez Silvia Romano Romero